Corazon (Corsee) D. Sanders

CIK 1796536 · last filed 2026-10-01

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.21M
Companies
6
Total Filings
48
Lifetime Open-Market Net
-$2.56M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

ONC price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O MOLECULAR TEMPLATES, INC.
9301 AMBERGLEN BLVD, SUITE 100
AUSTIN, VI 78729
Related Filers
Ultragenyx Pharmaceutical Inc. — 18 joint filings, latest 2026-06-15
BeiGene, Ltd. — 17 joint filings, latest 2026-08-25
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LEGN Director 52,731 $16.16 $852.4K -$258.9K 2 2026-10-01
CLDI Director — $0.52 — $0 1 2026-08-19
RARE Director 21,095 $17.18 $362.4K -$339.4K 11 2026-06-15
ONC Director 0 $400.21 $0 -$1.86M 4 2026-05-27
Molecular Templates, Inc. (MTEM) Delisted Director — $0.00 — $0 6 2024-09-30
BeOne Medicines Ltd. (BGNE) Delisted Director 46,241 $184.71 $8.54M -$105.4K 6 2024-06-07

10b5-1 Trading Plans

2 plans · 1 in force
Plans this person adopted or ended, as the company reported them in its 10-Q or 10-K. A Rule 10b5-1 plan sets trades in advance; a director's or officer's plan can't sell until a cooling-off period ends, 90 to 120 days after adoption. Sold so far adds up the open-market sales filed on Form 4 under a plan since it was adopted, and the percentage is of the shares the plan allows.
Company Adopted Sales Can Start Ends Plan Allows Sold So Far Status Link
RARE
Board Member
Nov 15, 2024 Feb 21, 2025 Jun 27, 2025 2,405 shares 2,405 (100%)
last filed Jun 23, 2025
Ended 10-K
RARE
member of the Company’s Board of Directors
Nov 10, 2023 Feb 23, 2024 — 2,322 shares 4,726
last filed Jun 23, 2025
Active 10-K
Sales can start: the later of 90 days after adoption and two business days after the report for the quarter it was adopted in, capped at 120 days. Ends: the end date the company gave, or adoption plus the plan's stated length; a plan can also end sooner once its shares are sold. Ended early means the company reported the plan terminated before that date. Sold so far is left blank while a plan is cooling off, and when a stock split falls inside the plan the percentage is left out because the limit is in pre-split shares.

Recent Filings · Page 5 of 5

48 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2022-06-24 BeOne Medicines Ltd. (BGNE) Delisted Grant (A) +16,692 $0 EDGAR
2022-06-06 Molecular Templates, Inc. (MTEM) Delisted Grant (A) — $0 EDGAR
2021-06-30 RARE Grant (A) +3,895 $0 EDGAR
2021-06-21 BeOne Medicines Ltd. (BGNE) Delisted Grant (A) +7,800 $0 EDGAR
2021-06-04 Molecular Templates, Inc. (MTEM) Delisted Grant (A) — $0 EDGAR
2020-08-26 BeOne Medicines Ltd. (BGNE) Delisted Grant (A) — $0 EDGAR
2020-06-01 Molecular Templates, Inc. (MTEM) Delisted Grant (A) — $0 EDGAR
2019-12-20 Molecular Templates, Inc. (MTEM) Delisted Grant (A) — $0 EDGAR
Showing 41–48 of 48
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).

Sales Reported Only on Form 144

5 sales · $1.24M
Each Form 144 lists the seller's sales of the company's stock in the 3 months before it. These are the sales on this filer's notices that no Form 4 on file shows, which is the usual case once someone is no longer an officer or director, or for an affiliate who never files Form 4s. Each sale is listed once, with the first notice that reported it.
Sold Symbol Shares Proceeds Avg Price Listed On
2026-06-15 BeOne Medicines Ltd. 945 $250.9K $265.50 2026-08-25
2026-05-22 BeOne Medicines Ltd. 212 $65.6K $309.59 2026-06-15
2025-09-05 BeOne Medicines Ltd. 2,665 $898.1K $337.00 2025-11-26
2025-06-24 Legend Biotech Corp 307 $10.6K $34.37 2025-09-23
2025-03-25 Legend Biotech Corp 307 $11.2K $36.33 2025-06-24